SOTAC — Sotac Pharmaceuticals Share Price
Last trade - 00:00- IN₹1.38bn
- IN₹1.69bn
- IN₹1.04bn
- 12
- 27
- 51
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.93 | ||
| Price to Tang. Book | 3.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.32 | ||
| EV to EBITDA | 20.63 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.01% | ||
| Return on Equity | 9.24% | ||
| Operating Margin | 4.78% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 286.04 | 488.43 | 731.52 | 579.83 | 1,038.31 | n/a | n/a | 38.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +12.27 | -20.38 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sotac Pharmaceuticals Limited is an India-based pharmaceutical company. The Company's services include contract manufacturing, loan license, formulation and development (F & D) and research and development (R & D). It specializes in manufacturing a range of pharmaceutical products having a therapeutic portfolio including anti-diabetic, anti-psychotic, vitamins, minerals, iron, anti-cold, anti-allergic, dermatological products, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics (IP-Lactams & Non-IP-Lactams), anti-fungal and cephalosporin. It also manufactures nutraceuticals products and food products on contract-manufacturing basis. Its products are supplied across 14 states in India, and it exports its products to over 20 countries worldwide. Its subsidiaries include Sotac Healthcare Private Limited, Sotac Lifesciences Private Limited and Sotac Research Private Limited.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- December 18th, 2015
- Public Since
- April 13th, 2023
- No. of Employees
- 89
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 11,050,000
- Address
- Sanand, Plot No. Pf-21, AHMEDABAD, 382110
- Web
- https://sotacpharma.com/
- Phone
- +91 null9081993300
- Auditors
- Keyur Shah & Co
Similar to SOTAC
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 23:21 UTC, shares in Sotac Pharmaceuticals are trading at IN₹124.95. This share price information is delayed by 15 minutes.
Shares in Sotac Pharmaceuticals last closed at IN₹124.95 and the price had moved by +0.73% over the past 365 days. In terms of relative price strength the Sotac Pharmaceuticals share price has underperformed the S&P BSE 100 Index by -5.12% over the past year.
There is no consensus recommendation for this security.
Find out moreSotac Pharmaceuticals does not currently pay a dividend.
Sotac Pharmaceuticals does not currently pay a dividend.
Sotac Pharmaceuticals does not currently pay a dividend.
To buy shares in Sotac Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹124.95, shares in Sotac Pharmaceuticals had a market capitalisation of IN₹1.38bn.
Here are the trading details for Sotac Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SOTAC
Based on an overall assessment of its quality, value and momentum Sotac Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sotac Pharmaceuticals. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -1.85%.
As of the last closing price of IN₹124.95, shares in Sotac Pharmaceuticals were trading -2.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sotac Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹124.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Sotac Pharmaceuticals' directors